• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Companies that Ward Off ESG and Reputation Crises See Value Surge

    3/8/22 8:00:00 AM ET
    $APO
    $CVS
    $FB
    $JNJ
    Investment Managers
    Finance
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $APO alert in real time by email

    PITTSBURGH, March 8, 2022 /PRNewswire-PRWeb/ -- Companies with ESG and reputational risk protection strategies have seen their stock prices rise 5% above the market within two weeks of a reputational challenge, and that premium is almost double for companies that have publicly shared and validated those strategies.

    The study, by Steel City Re, an ESG and reputation insurer, also found that stock prices of firms that managed, validated and publicized ESG and reputation risk management strategies on average gained 9.3% over the subsequent seven months after a precipitating event, while firms in which such processes were in assumed by shareholders to be in place gained 4.3%. Companies that failed to institute, validate, and communicate risk management strategies lost 13.2% of their stock value over those seven-month periods, and they underperformed their peers by an average of 23.3%.

    "Investors appear to reward firms that actively manage reputational risks as operational strategies and not just potential PR problems," said Nir Kossovsky, Steel City Re's CEO. "Our study makes the case for ESG-focused firms to take a more structured, substantive and comprehensive approach to risk governance and management."

    "The data show that instituting, validating, and communicating risk management strategies can both fulfill the goals of stakeholder-centrism and meet shareholder expectations," he added.

    Illustrative highlights include:

    • Johnson & Johnson (NYSE:JNJ) outperformed the market by 16% ($1.7bn) when its much publicized strategic supply chain security and product safety processes were proven effective in 1986.
    • Rolls Royce (OTC:RYCEY), whose board defined its risk governance mission as protecting the reputation, viability, and profitability of the firm, outperformed the market by 14.9% ($3.4bn) after it proved the quality of its safety controls throughout its supply chain in 2011.
    • Apollo Global Management (NYSE:APO) outperformed the market by 16.6% ($1.9bn) after it announced an ESG-focused governance reorganization and presented in 2021 and independent validation of a 3-year investment in reputation risk management.
    • CVS (NYSE:CVS) outperformed the market by 9.3% ($8.6bn) when, presciently anticipating the ESG movement, it pursued an ethical innovative strategy that shunned tobacco products in 2014. It outperformed rivals Walgreens (NYSE:WBA) and Rite Aid (NYSE:RAD) by 16.6% and 24.8% respectively.
    • Apple (NADQ:AAPL) outperformed the market by 24% ($505bn) after introducing innovative ethical privacy features that addressed a critical ESG concern in the technology sector in 2021. It outperformed Meta (NYSE:FB), facing a range of privacy challenges, by 34.9%.

    About the Study

    The Steel Re study looked at seven firms that took direct action to publicize their reputation risk management and governance, 20 firms whose protection strategies were in assumed by shareholders to be in place because of their response to external events, 20 firms whose strategies were shown to be insufficient over seven months, and from among these, 22 firms whose reputational impairment and value losses were measured against peer competitors.

    The reputational challenges were all public events over the past 15 years supplemented by iconic cases of Johnson & Johnson's two Tylenol-related safety events of the 1980's. Individual gains and losses were calculated after normalizing for changes in the S&P500, and the date for ESG and reputational events was determined by a marked surge in stakeholder interest as explored in a related Steel City Re white paper.

    About Steel City Re

    Steel City Re provides parametric ESG insurance, reputational insurance and helps guide companies' boards and senior leadership in developing enhanced risk governance and management practices. Its underwriting model is supported by more than 7.3 million measures of reputational value and traditional financial metrics that also fuel ESG-focused hedge fund strategies. Its risk governance and management models are informed by principles of behavioral economics.

    Media Contact

    Desiree Niccoli, Steel City Re, 412-804-8649, desiree@alschulerpr.com

    Steve Alschuler, Steel City Re, 917-647-2151, steve@alschulerpr.com

     

    SOURCE Steel City Re

    Get the next $APO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APO
    $CVS
    $FB
    $JNJ

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    5/13/2026$265.00Market Perform → Outperform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    4/8/2026$250.00Buy
    TD Cowen
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    Apollo Global Management Inc. (New)
    $APO
    2/24/2026$142.00Sector Perform
    RBC Capital Mkts
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Apollo Global Management Inc. (New)
    $APO
    12/11/2025$186.00Buy
    UBS
    Apollo Global Management Inc. (New)
    $APO
    11/20/2025$180.00Equal-Weight → Overweight
    Morgan Stanley
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    More analyst ratings

    $APO
    $CVS
    $FB
    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    SEC Filings

    View All

    SEC Form SD filed by Johnson & Johnson

    SD - JOHNSON & JOHNSON (0000200406) (Filer)

    5/27/26 4:15:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by CVS Health Corporation

    S-8 - CVS HEALTH Corp (0000064803) (Filer)

    5/22/26 4:28:36 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form S-3ASR filed by CVS Health Corporation

    S-3ASR - CVS HEALTH Corp (0000064803) (Filer)

    5/22/26 4:27:23 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00

    5/13/26 7:59:34 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of its ultimate parent, CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.)Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary of Ae

    6/5/26 4:35:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

    Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren's disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and painNipocalimab is the only FcRn blocker

    6/3/26 12:03:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollo Funds Complete Sale of ALTEMIRA, Leading Pan-Asian Aluminum Packaging Company

    TOKYO and NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE:APO) announced that Apollo-managed funds (the "Apollo Funds") completed the sale of their interest in ALTEMIRA Holdings Co., Ltd. ("ALTEMIRA" or the "Company"), a leading pan-Asian aluminum packaging company, to funds managed by MBK Partners. ALTEMIRA was established in April 2022, through the combination of the aluminum can and foil business formerly operated by Showa Denko K.K. (now named Resonac Holdings Corporation) and the aluminum can and rolled and extruded products business of Mitsubishi Materials Corporation. ALTEMIRA is one of the first successful examples of sponsor-led industry consolidation in the Japanese ind

    6/2/26 7:00:00 PM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Financial Officer Newman Brian covered exercise/tax liability with 2,478 shares, decreasing direct ownership by 45% to 3,008 units (SEC Form 4) (withholding obligation)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/1/26 5:02:36 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Medical Officer Compton-Phillips Amy covered exercise/tax liability with 7,618 shares, decreasing direct ownership by 44% to 9,557 units (SEC Form 4) (tax withholding)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/1/26 5:00:41 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Aguirre Fernando returned $3,000,372 worth of shares to the company (32,000 units at $93.76), decreasing direct ownership by 75% to 10,513 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    5/22/26 5:39:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Stream Data Centers' Executive Leadership Expands to Meet Accelerated Hyperscale Demand, Deliver Efficient, Capital-Backed Results

    New Chief Financial Officer and Executive Vice President of Construction Empower Trusted Leasing and Delivery Strategies Built for Evolving Customer Requirements Stream Data Centers, a time-tested hyperscale partner and one of the longest-standing developers in the industry, announces two new additions to its leadership team: Murray Woolcock, Chief Financial Officer, and Scott Greubel, Executive Vice President, Construction. Offering more than 50 years of combined experience, Woolcock and Greubel empower Stream's growth to meet hyperscale customer requirements with reliable, configurable, and scalable deal structures and construction strategies. "The fact that both Murray and Scott be

    5/14/26 9:03:00 AM ET
    $APO
    Investment Managers
    Finance

    Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

    Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430443361/en/Ryan Koors, Vice President, Investor Relations, Johnson & Johnson, effective May 7, 2026. "Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitm

    4/30/26 8:02:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bridge Investment Group Appoints Dugan Fife as Head of Wealth Solutions

    SALT LAKE CITY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Bridge Investment Group Holdings Inc. ("Bridge" or the "Company"), today announced that Dugan Fife has been appointed Head of Wealth Solutions and Senior Managing Director, effective January 19. Fife will lead the firm's efforts to expand and enhance its wealth solutions platform, delivering innovative investment opportunities and tailored strategies to meet the evolving needs of private wealth clients. Fife joins a high-performing Wealth distribution team at Bridge that serves clients through core investment verticals including Residential, Industrial, Real Estate Credit, and Net Lease. "Dugan's exceptional track record and experience lea

    1/20/26 8:35:00 AM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Financials

    Live finance-specific insights

    View All

    AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of its ultimate parent, CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.)Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary of Ae

    6/5/26 4:35:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    ARCTRUST Acquires Seven Property Net Lease Portfolio for Planned DST Offering

    Diversified portfolio of Pinnacle Bank, CVS Pharmacy, and NAPA Auto Parts properties expands ARCTRUST's net lease platform for 1031 exchange investors ARCTRUST Private Capital, the capital markets division of the ARCTRUST Group of Companies, announced today the acquisition of a seven property, single-tenant net lease portfolio comprised of two Pinnacle Bank locations, three CVS Pharmacy locations, and two NAPA Auto Parts locations across six states. The portfolio will be offered to accredited investors as a Delaware statutory trust (DST): ARCTRUST Exchange II DST. The seven property portfolio consists of approximately 51,192 net rentable square feet across a combined land area of around

    5/28/26 8:00:00 AM ET
    $CVS
    $GPC
    $PNFP
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Automotive Aftermarket
    Consumer Discretionary

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the w

    5/27/26 4:22:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples